Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction

Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652–61.

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancerbase no. 11 [Internet]. Lyon. France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr .

Neuss MN, Polovich M, McNiff K, Esper P, Gilmore TR, LeFebvre KB, et al. 2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. J Oncol Pract. 2013;9(2 Suppl.):S5–13.

Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm. 2007;64:4–7.

Institute for Safe Medications Practices. ISMP’s list of high-alert medications. Huntingdon Valley: ISMP; 2014. http://www.ismp.org/tools/highalertmedications.pdf (Accessed 27 Jan 2015).

Goodin S, Griffith N, Chen B, Chuk K, Daouphars M, Doreau C, et al. Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. J Oncol Pract. 2011;7:7–12.

Walsh KE, Dodd KS, Seetharaman K, Roblin DW, Herrinton LJ, Von Worley A, et al. Medication errors among adults and children with cancer in the outpatient setting. J Clin Oncol. 2009;27:891–6.

Kruse V, Somers A, Van Bortel L, De Both A, Van Belle S, Rottey S. Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug–drug interactions. J Clin Pharm Ther. 2014;39:259–65.

Narasimhan NI, Dorer DJ, Niland K, Haluska F, Sonnichsen D. Effects of food on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharm Ther. 2013;38:440–4.

Weingart SN, Flug J, Brouillard D, Harway L, Partridge A, Bartel S, et al. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ. 2007;334:407–9.

Abramowitz PW, Shane R, Daigle LA, Noonan KA, Letendre DE. Pharmacist interdependent prescribing: a new model for optimizing patient outcomes. Am J Health Syst Pharm. 2012;69:1976–81.

Lexi-comp ONLINE [Internet]. Hudson: Lexi-Comp; 1978. http://online.lexi.com/crlsql/servlet/crlonline (Accessed 28 Nov 2014).

Van Mil F. Drug-related problems: a cornerstone for pharmaceutical care. J Malta College Pharm Pract. 2005;10:5–8.

National Cancer Institute. Common terminology criteria for adverse events (CTCAE), version 4.03. Bethesda. US Department of Health and Human Services, National. Institutes of Health; 2010. (Accessed 4 Nov 2014).

Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381–8.

Wong SF, Bounthavong M, Nguyen C, Bechtoldt K, Hernandez E. Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic. Am J Health Syst Pharm. 2014;71:960–5.

Cavanaugh JJ, Lindsey KN, Shilliday BB, Ratner SP. Pharmacist-coordinated multidisciplinary hospital follow-up visits improve patient outcomes. J Manag Care Spec Pharm. 2015;21:256–60.

Li E, Schleif R, Edelen B. Hospital management of outpatient oncology treatment decisions: a survey to identify strategies and concerns. J Oncol Pract. 2013;9:248–54.

Bulsink A, Imholz AL, Brouwers JR, Jansman FG. Characteristics of potential drug-related problems among oncology patients. Int J Clin Pharm. 2013;35:101–7.

Aimono Y, Nemoto M, Sato W, Saito Y, Aoyama Y, Joko F, et al. Examination of the usefulness of the pharmacists’ outpatient clinic for treatment with oral molecule-targeting drugs. Gan To Kagaku Ryoho. 2013;40:901–5.

Cornelison M, Jabbour EJ, Welch MA. managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. J Support Oncol. 2012;10:14–24.

Folsche, M. Management of chemotherapy-related symptoms by telephone aftercare by an oncology nurse. Eur. J. Cancer Suppl. 2009; 7(2):231. doi: 10.1016/S1359-6349(09)70790-6

Bassan F, Peter F, Houbre B, Brennstuhl MJ, Costantini M, Speyer E, Tarquino C, et al. Adherence to oral antineoplastic agents by cancer patients: definition and literature review. Eur J Cancer Care. 2014;23:22–35.

Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007;25:481–96.